Mechanistic Insights into Aryl Hydrocarbon Receptor Regulation of Fibroblast Growth Factor 21 and its Influence on Systemic Energy Metabolism
Mechanistic Insights into Aryl Hydrocarbon Receptor Regulation of Fibroblast Growth Factor 21 and its Influence on Systemic Energy Metabolism
批准号:
9760975
负责人:
Nathaniel Girer
金额:
$6.12万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2020-03-31
关键词:
ARNT geneAddressAdipose tissueAgonistArchitectureAryl Hydrocarbon ReceptorAttenuatedBHLH ProteinBindingBinding ProteinsBiological ProductsBiologyBody Weight decreasedBrown FatCRISPR/Cas technologyCell NucleusChemicalsChromatinClinical TrialsComplexCytosolDNA BindingDNA SequenceDataDepositionDietDietary FatsDioxinsDropsEndocrineEnergy MetabolismEnvironmentEnvironmental PollutionEventExposure toFGF21 geneFatty acid glycerol estersFemaleGene ExpressionGenesGeneticGenetic TranscriptionGrantHepaticHepatocyteHigh Fat DietHomeostasisHumanInterruptionKnock-outKnockout MiceKnowledgeLigandsLinkLipidsLiverMediatingMentorsMetabolic DiseasesMetabolic hormoneMethodologyMethodsMitochondriaModelingMolecularMolecular ChaperonesMusObesityOutputPhenotypePhysiological ProcessesPlayProductionProductivityPromoter RegionsProtein FamilyProteinsPublicationsRegulationResearchResearch PersonnelRespirationResponse ElementsRoleSiteTechniquesTestingTetrachlorodibenzodioxinToxic effectTrainingTranscriptional RegulationWeight Gaincareer developmentchromatin immunoprecipitationdruggable targetexperimental studyfibroblast growth factor 21glucose metabolismimprovedin vivoinnovationinsightmouse modelnovelpromoterprotective effectreceptorreceptor bindingreceptor expressionreconstitutionresponsesuccesstherapeutic developmenttherapeutic targettherapy developmenttranscription factoruncoupling protein 1
中文摘要
摘要
这个项目的长期目标是获得关于芳基作用的基本知识
碳氢化合物受体(AHR)在能量代谢中的作用,并更好地了解
代谢性疾病 AHR是一种配体激活的转录因子,通过位点调控基因表达
特异性DNA结合。 最近的数据表明,AHR参与了代谢产物的转录调节。
激素成纤维细胞生长因子21(FGF 21)。 FGF 21从肝脏分泌,并促进产热性
棕色脂肪组织--在白色脂肪沉积物中的类脂肪表型。各种模型中的外源性FGF 21给药
肥胖症的预防和治疗一贯导致体重增加和脂肪沉积减少。 我以前的数据表明,
几种不同转录因子对Fgf 21基因表达的激活作用,
AHR激动剂,但其机制尚不清楚。自从最初提交以来,我已经生成了数据,
证明AHR损失促进体重减轻、肝细胞FGF 21输出和棕色脂肪的形成。
性腺周围白色脂肪组织(gWAT)中的组织-脂肪样表型。利用肝细胞靶向AHR-bFGF 21
在双敲除(DKO)小鼠模型中,我进一步表明这种表型依赖于FGF 21表达。
初步数据表明,AHR损失通过减轻体重来防止高脂饮食(HFD)的挑战
增益和肥胖。所提出的研究的基本假设是,AHR损失释放组成
Fgf 21转录的AHR-β依赖性抑制以防止HFD-β诱导的肥胖。 为了验证这一
假设,提出了两个具体目标。 第一个具体目标将描述AHR缺失如何能够
通过增加肝细胞FGF 21的产生来保护免受高脂饮食的挑战,
将AHR表达重新引入AHR-1缺陷小鼠和FGF 21的复杂体内方法
在DKO小鼠中表达。 具体目标二将询问AHR调节的机制
天然染色质环境中的fgf 21转录。 染色质免疫沉淀及其研究进展
CRISPR/Cas9基因编辑技术将用于这一目标,以协调AHR激动剂-β-内酰胺酶驱动的变化,
Fgf 21基因表达与Fgf 21启动子内三个特异性DRE处的时间AHR结合事件。
成功完成拟议的研究将提供一个全面的评估,
调节肝脏Fgf 21表达,有助于培养对AHR在肝纤维化中作用的更好分子理解。
能量稳态,并可能确定AHR作为一个潜在的“药物”的发展目标,
针对代谢性疾病的治疗性治疗。 符合申请人的职业发展
目标,拟议的创新实验和指导培训计划是量身定制的,以提供培训,
先进的技术,并协助过渡到独立。
英文摘要
ABSTRACT
The long-term objectives of this project are to acquire fundamental knowledge about the role of aryl
hydrocarbon receptor (AHR) in energy metabolism and to better understand the mechanistic underpinnings of
metabolic disease. The AHR is a ligand-activated transcription factor that regulates gene expression via site-
specific DNA binding. Recent data have implicated the AHR in transcriptional modulation of the metabolic
hormone fibroblast growth factor 21 (FGF21). FGF21 is secreted from the liver and promotes a thermogenic
brown adipose tissue-like phenotype in white fat deposits. Exogenous FGF21 administration in various models
of obesity consistently results in reduced weight gain and fat deposition. My previous data indicate that the
activation of Fgf21 gene expression by several different transcription factors is attenuated with pre-exposure to
AHR agonist, but the mechanism for this is unclear. Since the original submission, I have generated data that
demonstrate AHR loss promotes weight loss, hepatocyte FGF21 output, and the formation of a brown adipose
tissue-like phenotype in perigonadal white adipose tissue (gWAT). Utilizing a hepatocyte-targeted AHR-FGF21
double knockout (DKO) mouse model, I further show that this phenotype is dependent upon FGF21 expression.
Preliminary data indicate that AHR loss protects against a high-fat diet (HFD) challenge by reducing weight
gain and adiposity. The underlying hypothesis of the proposed research is that AHR loss releases constitutive
AHR-dependent suppression of Fgf21 transcription to protect against HFD-induced obesity. To test this
hypothesis, two specific aims are proposed. The first specific aim will characterize how AHR deletion can
protect against high-fat dietary challenge through increased hepatocyte FGF21 production, and employs a
sophisticated in vivo methodology to reintroduce AHR expression into AHR-deficient mice and FGF21
expression into DKO mice. Specific aim two will interrogate the mechanism via which the AHR modulates
Fgf21 transcription within a native chromatin setting. Chromatin immunoprecipitations and state-of-the-art
CRISPR/Cas9 gene-editing techniques will be used in this aim to reconcile AHR agonist-driven changes in
Fgf21 gene expression with temporal AHR binding events at three specific DREs within the Fgf21 promoter.
Successful completion of the proposed studies will provide a comprehensive assessment of how the AHR
modulates hepatic Fgf21 expression, help cultivate a better molecular understanding of the role of the AHR in
energy homeostasis, and may identify the AHR as a potential ‘druggable’ target in the development of
therapeutic treatments against metabolic disease. Consistent with the applicant’s career development
objectives, the proposed innovative experiments and mentored training plan are tailored to provide training in
sophisticated techniques and to aid in the transition to independence.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金